Establishment method of animal model for ipv intradermal immunity evaluation

Abstract

The invention provides an establishment method of an animal model for evaluating IPV (inactivated poliovirus vaccine) intradermal immunization effectiveness. The establishment method includes the following steps: selecting Yunnan Xishuangbanna small ear pigs belonging to Southern China pigs, with pig ages of 3-5 months and weights of 10-20kg, randomly grouping the pigs, respectively injecting an IPV vaccine through needleless intradermal injection for the first time, sampling blood after immunity for 30 days, separating serum, respectively injecting the IPV vaccine through needleless intradermal injection for the second time, sampling blood after immunity for 7 days and 30 days, separating the serum, respectively injecting the IPV vaccine through needleless intradermal injection for the third time, sampling blood after immunity for 1 month, 6 months, 12 months, 18 months and 24 months, separating the serum, inactivating the serums for 30 minutes at 56 DEG C, conventionally diluting the serums, neutralizing the serums by using Sabin strain I type and II type and Pfizer III type viruses, wherein the dosage of the viruses is 30-300 TCID50 (tissue culture infectious dose 50), naturalizing for 3 hours at 35-37 DEG C, adding cells, culturing at 35-36 DEG C for 7 days, and judging a result according to CPE (Cytopathic Effect), thus establishing the animal model for evaluating IPV intradermal immunization effectiveness. By adopting the establishment method provided by the invention, a rational animal model is provided for an intradermal immunization research on vaccines, and a reliable measure is provided for reducing the dosage of vaccine antigen in the intradermal immunization research.

Description

technical field [0001] The invention relates to a method for establishing an animal model for intradermal safety and immunogenicity evaluation of a vaccine, in particular to a method for establishing a miniature pig animal model for intradermal immune evaluation of an inactivated polio vaccine, and belongs to the field of medical biotechnology. Background technique [0002] Poliomyelitis is an acute infectious disease caused by poliovirus types Ⅰ, Ⅱ, and Ⅲ, which is widely spread and extremely harmful. The clinical symptoms will quickly cause irreversible paralysis, causing flaccid paralysis of muscles, especially limbs, which mostly occurs in children, so it is also called "poliomyelitis". In the mid-to-late 1950s, two scientists in the United States, Dr. Jonas Salk and Dr. Albert Sabin, successively successfully developed inactivated polio vaccine (IPV) and oral polio vaccine (OPV) to prevent and eliminate polio. Yan provides a powerful weapon. Live attenuated polio vacc...

AI Technical Summary

Problems solved by technology

[0005] The traditional intramuscular injection route of IPV is used to evaluate the efficacy of Wistar rats as an experimental animal model. There is no report on the efficacy of intradermal immunization route of IPV.

Images